A pooled analysis of elderly patients (those aged 75 years and over) with advanced NSCLC with PDL1-positive have indicated that pembrolizumab not only improved OS but presented a more favorable safety profile versus chemotherapy (Nosaki et al., 2019). The gene discussed is CD274; the disease is non-small cell lung carcinoma.